Every Form 4 that Catheter Precision, Inc. (VTAK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VTAK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTAK filings page.
Catheter Precision, Inc. reported that Chairman and CEO David A. Jenkins received a grant of options to buy 40,000 shares of common stock. The options have an exercise price of $1.15 per share, expire on March 26, 2036, and vest 100% 180 days after the grant date.
Catheter Precision, Inc. reported that its Chief Financial Officer, Philip J. Anderson, received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $1.15 per share and expire on March 26, 2036.
The options were awarded as a compensation grant and vest 100% on the 180-day anniversary of the grant date. Following this grant, Anderson holds derivative securities representing rights to acquire 40,000 shares of Catheter Precision common stock through these options.
Catheter Precision, Inc. director Arno Andrew received a grant of stock options as part of his compensation. The award covers 40,000 options to buy common stock at an exercise price of $1.15 per share, expiring on March 26, 2036. The options vest 100% on the 180-day anniversary of the grant date, and following this grant he holds 40,000 derivative securities of this type directly.
Catheter Precision, Inc. director James Joseph Caruso received a grant of options to buy 40,000 shares of common stock. The options have an exercise price of $1.15 per share and expire on March 26, 2036. According to the grant terms, the options vest 100% on the 180-day anniversary of the grant date.
Catheter Precision, Inc. director Martin J. Colombatto received a grant of stock options on Common Stock. The award covers 40,000 options with an exercise price of $1.15 per share, expiring on March 26, 2036. The options vest 100% on the 180-day anniversary of the grant date, and following this grant he holds 40,000 options directly.
Catheter Precision, Inc. chairman and CEO David A. Jenkins reported two Form 4 transactions involving Series J Preferred Stock. The Series J shares were issued under an exchange agreement that cancels an accrued royalty amount and terminates a royalty right in return for this preferred stock, as described in a related Form 8-K. Jenkins holds 2,491.293 Series J shares directly and 6,998.195 Series J shares indirectly through FatBoy Capital LP, whose general partner is SeaCap Management LLC, where he is managing member. The Series J Preferred Stock is not exercisable until stockholder approval is received and it has no expiration date.
Catheter Precision, Inc. Chairman and CEO David A. Jenkins reported derivative holdings in Series M Common Stock Purchase Warrants. On December 31, 2025, he reported 170,000 Series M warrants at an exercise price of $1.56 per underlying common share held directly, and another 170,000 Series M warrants at the same exercise price held indirectly.
The warrants are initially exercisable any time on or after the stockholder approval date, and each warrant terminates on the five and one half year anniversary of its initial exercise date. The indirect position is associated with FatBoy Capital LP, whose general partner is SeaCap Management LLC, where Mr. Jenkins serves as managing member.
Catheter Precision, Inc. director James J. Caruso reported a small equity transaction in the company’s stock. On 12/05/2025, he acquired 41 shares of common stock at a price of $0 per share in a transaction coded “C,” indicating a conversion. Following this transaction, he directly beneficially owned 50 shares of common stock.
The filing also shows activity in Series X Convertible Preferred Stock, with a conversion price of $0. On the same date, 7.932 shares of this preferred stock were involved in a transaction coded “C,” with no common shares shown as underlying afterward and 0 derivative securities beneficially owned. The accompanying note explains that the Series X Convertible Preferred Stock has no expiration date.
Catheter Precision, Inc. reported an insider stock transaction by its Chairman and CEO, David A. Jenkins. On 12/05/2025, Jenkins converted shares of Series X Convertible Preferred Stock into common stock at a stated price of $0 per share. Following these conversions, he directly held 13,799 common shares, with an additional 34,579 shares held indirectly through a partnership and 109 shares held indirectly through a charitable remainder unitrust. The filing notes that the preferred stock has no expiration date and that some of the indirectly held shares are controlled via entities managed by Jenkins or his spouse, clarifying the structure of his beneficial ownership.